{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:50:42Z","timestamp":1788263442136,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13365-017-0561-9","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T09:19:15Z","timestamp":1502183955000},"page":"742-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scarpazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Imberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Cordioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,8]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","unstructured":"Auer M, Borena W, Laer DH, Deisenhammer F (2016) Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr-virus and -measles\/-rubella\/-varicella-zoster-virus antibodies. J Med Virol doi. doi:\n10.1002\/jmv.24590","DOI":"10.1002\/jmv.24590"},{"key":"561_CR2","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000274","volume":"3","author":"M Baharnoori","year":"2016","unstructured":"Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3:e274","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"561_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","volume":"12","author":"JR Berger","year":"2017","unstructured":"Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59\u201363","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"561_CR4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15):1430\u20131438","journal-title":"Neurology"},{"key":"561_CR5","unstructured":"Biogen International (2016) hcp.\nbiogen-international.com\/tysabri_update.aspx?ID=22076\n\n (accessed 30 December 2016)"},{"key":"561_CR6","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"561_CR7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M et al (2011) Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742\u2013750","journal-title":"Ann Neurol"},{"key":"561_CR8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","volume":"21","author":"C Bozic","year":"2014","unstructured":"Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B (2014) Anti-JC virus (JCV) antibody prevalence in the JCV epidemiology in MS (JEMS) trial. Eur J Neurol 21:299\u2013304","journal-title":"Eur J Neurol"},{"key":"561_CR9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"561_CR10","unstructured":"CTCAE (2010) Common Terminology Criteria for Adverse Events version 4.03; \nhttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm\n\n (accessed 20 June 2017)"},{"key":"561_CR11","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","volume":"20","author":"GR Cutter","year":"2014","unstructured":"Cutter GR, St\u00fcve O (2014) Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 2014 20:1304\u20131305","journal-title":"Mult Scler 2014"},{"key":"561_CR12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fnins.2015.00172","volume":"9","author":"M Deleidi","year":"2015","unstructured":"Deleidi M, J\u00e4ggle M, Rubino G (2015) Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci 9:172","journal-title":"Front Neurosci"},{"key":"561_CR13","first-page":"637","volume":"21","author":"T Dong-Si","year":"2015","unstructured":"Dong-Si T, Gheuens S, Gangadharan A et al (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neuro-Oncol 21:637\u2013644","journal-title":"J Neuro-Oncol"},{"key":"561_CR14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40263-014-0160-8","volume":"28","author":"RA Pasquier Du","year":"2014","unstructured":"Du Pasquier RA, Pinschewer DD, Merkler D (2014) Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs 28:535\u2013558","journal-title":"CNS Drugs"},{"key":"561_CR15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/EDE.0b013e3182576cdb","volume":"23","author":"I Eekhout","year":"2012","unstructured":"Eekhout I, de Boer RM, Twisk JW, de Vet HC, Heymans MW (2012) Missing data: a systematic review of how they are reported and handled. Epidemiology 23:729\u2013732","journal-title":"Epidemiology"},{"key":"561_CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"A Egli","year":"2009","unstructured":"Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837\u2013846","journal-title":"J Infect Dis"},{"key":"561_CR17","unstructured":"European Medicine Agency (2016) \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Tysabri_20\/European_Commission_final_decision\/WC500202394.pdf\n\n (accessed 24 January 2017)"},{"key":"561_CR18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K et al (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471\u2013506","journal-title":"Clin Microbiol Rev"},{"key":"561_CR19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","volume":"20","author":"G Francis","year":"2014","unstructured":"Francis G, Kappos L, O\u2019Connor P, Collins W, Tang D, Mercier F et al (2014) Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 20:471\u2013480","journal-title":"Mult Scler"},{"key":"561_CR20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.0000000000002330","volume":"86","author":"MS Gagne-Brosseau","year":"2016","unstructured":"Gagne-Brosseau MS, Stobbe G, Wundes A (2016) Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay. Neurology 86:484\u2013486","journal-title":"Neurology"},{"key":"561_CR21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","volume":"81","author":"S Gheuens","year":"2010","unstructured":"Gheuens S, Pierone G, Peeters P, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 81:247\u2013254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"561_CR22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","volume":"86","author":"TV Gyang","year":"2016","unstructured":"Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L (2016) Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 86:1843\u20131845","journal-title":"Neurology"},{"key":"561_CR23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174005","volume":"12","author":"H Hegen","year":"2017","unstructured":"Hegen H, Auer M, Bsteh G et al (2017) Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study. PLoS One 12:e0174005","journal-title":"PLoS One"},{"key":"561_CR24","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1212\/WNL.41.11.1733","volume":"41","author":"RC Holman","year":"1991","unstructured":"Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC (1991) Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 41:1733\u20131736","journal-title":"Neurology"},{"key":"561_CR25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.20933","volume":"60","author":"IJ Koralnik","year":"2006","unstructured":"Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 60:162\u2013173","journal-title":"Ann Neurol"},{"key":"561_CR26","doi-asserted-by":"crossref","first-page":"e0174858","DOI":"10.1371\/journal.pone.0174858","volume":"12","author":"J Kr\u00e4mer","year":"2017","unstructured":"Kr\u00e4mer J, Tenberge JG, Kleiter I et al (2017) Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? PLoS One 12:e0174858","journal-title":"PLoS One"},{"key":"561_CR27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/WNL.0000000000002900","volume":"87","author":"K Lehmann-Horn","year":"2016","unstructured":"Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B et al (2016) PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology 87:440\u2013441","journal-title":"Neurology"},{"key":"561_CR28","unstructured":"Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH (2015) Older age, lower baseline ALC and recent natalizumab exposure are risk factors for DMF-induced lymphopenia. Mult Scler J Exp Transl Clin [pii: 2055217315596994]"},{"key":"561_CR29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G et al (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87:117\u2013125","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"561_CR30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.msard.2016.06.014","volume":"9","author":"JA Miranda Acu\u00f1a","year":"2016","unstructured":"Miranda Acu\u00f1a JA, Weinstock-Guttman B (2016) Influenza vaccination increases anti-JC virus antibody levels during treatment with natalizumab: case report. Mult Scler Relat Disord 9:54\u201355","journal-title":"Mult Scler Relat Disord"},{"key":"561_CR31","unstructured":"Ontaneda D (2016) \nhttp:\/\/www.neurology.org\/content\/86\/5\/484.extract\/reply#neurology_el_64584"},{"key":"561_CR32","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S et al (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associatedprogressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"issue":"12","key":"561_CR33","doi-asserted-by":"crossref","first-page":"e0168376","DOI":"10.1371\/journal.pone.0168376","volume":"11","author":"L Prosperini","year":"2016","unstructured":"Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, Capra R, Italian PML study group (2016) Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry. PLoS One 11(12):e0168376","journal-title":"PLoS One"},{"key":"561_CR34","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372:1476\u20131478","journal-title":"N Engl J Med"},{"key":"561_CR35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","volume":"88","author":"N Schwab","year":"2017","unstructured":"Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88:1197\u20131205","journal-title":"Neurology"},{"key":"561_CR36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425\u2013437","journal-title":"Lancet Neurol"},{"key":"561_CR37","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697\u20131704","journal-title":"Neurology"},{"key":"561_CR38","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","volume":"15","author":"C Warnke","year":"2013","unstructured":"Warnke C, Mausberg AK, Stettner M et al (2013) Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 15:1400\u20131408","journal-title":"Neurology"},{"key":"561_CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exger.2016.02.005","volume":"77","author":"M Weltevrede","year":"2016","unstructured":"Weltevrede M, Eilers R, de Melker HE, van Baarle D (2016) Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: a systematic review. Exp Gerontol 77:87\u201395","journal-title":"Exp Gerontol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-017-0561-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-017-0561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-017-0561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T10:47:34Z","timestamp":1508842054000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-017-0561-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,8]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s13365-017-0561-9","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,8]]}}}